Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Johnson, B.; Miller, V.; Amler, L.; Stern, H.; Soh, C.; O'connor, P.; Kabbinavar, F. |
| Abstract Title: | Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) |
| Meeting Title: | 15th ECCO - 34th ESMO Multidisciplinary Cancer Congress |
| Journal Title: | EJC Supplements |
| Volume: | 7 |
| Issue: | 3 |
| Meeting Dates: | 2009 Sep 20-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 1359-6349 |
| Publisher: | Pergamon-Elsevier Science Ltd |
| Date Published: | 2009-09-01 |
| Start Page: | 5 |
| End Page: | 6 |
| Language: | English |
| ACCESSION: | ISI:000270645000016 |
| PROVIDER: | wos |
| DOI: | 10.1016/S1359-6349(09)72037-3 |
| Notes: | Meeting Abstract: 8LBA -- "Source: Wos" |
